Ronald Herbst

AstraZeneca (Netherlands) — Netherlands

Medicine · Health Sciences

50h-index11.4kcitations329works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(79), Monoclonal and Polyclonal Antibodies Research(46), Lung Cancer Treatments and Mutations(43), Immune Cell Function and Interaction(43), Cytokine Signaling Pathways and Interactions(41)

Publications329 total

572 PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins

Regular and Young Investigator Award Abstracts·2023Open Access

Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies

5 cited

Journal of Cancer Immunology·2023· 5 citedOpen Access

Supplementary Figures S1-S7 from Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

2023Open Access

Data from Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

2023Open Access

Supplementary Table 1 from Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

2023Open Access

Data from Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

2023Open Access

Supplementary Figures S1-S7 from Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

2023Open Access

Supplementary Table 1 from Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

2023Open Access

Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Supplementary Figure S12 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Data from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Supplementary Table S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

Figure S2 from Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

2023Open Access

Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

2023Open Access

Supplementary Figure S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

2023Open Access

page 1 of 17Next →

Frequent Co-authors

Rachel Ettinger(7), Bahija Jallal(6), Jodi L. Karnell(5), Gary P. Sims(4), Jérôme Biton(4), Audrey Mansuet‐Lupo(4), Marco Alifano(4), Diane Damotte(4), Kathy Mulgrew(4), Chris Morehouse(4), Katie Streicher(4), Michael A. Bowen(4), Yue Wang(4), Daniel C. Rowe(3), Anthony J. Coyle(3), Elaine M. Hurt(3), Hanane Ouakrim(3), Jennifer Arrondeau(3), Pascaline Boudou‐Rouquette(3), François Goldwasser(3)